<DOC>
	<DOCNO>NCT02182206</DOCNO>
	<brief_summary>Maximum Tolerated Dose ( MTD ) , safety , pharmacokinetics , efficacy BIBF 1120 , pharmacodynamic parameter ( Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI ) )</brief_summary>
	<brief_title>An Dose Escalation Study Treatment With BIBF 1120 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Male female patient confirm diagnosis advance , non resectable and/or metastatic solid tumour , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment Measurable tumour deposit one technique ( Xray ) , Computed Tomography ( CT ) , Magnetic Resonance Imaging ( MRI ) ) At least one tumour lesion consider suitable DCEMRI determine discussion centre radiologist . This lesion must previously irradiate Age 18 year old Life expectancy least three month Written inform consent give consistent International Conference HarmonisationGood Clinical Practice ( ICHGCP ) guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Patients completely recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapies Surgical procedure within four week initiate treatment study drug , active ulcer , injury incomplete wound heal Active infectious disease Uncontrolled , severe hypertension ( diastolic BP ( Blood Pressure ) &gt; 100 mmHg , Systolic BP &gt; 180 mmHg ) Gastrointestinal disorder might interfere resorption study drug Serious illness concomitant nononcological disease consider investigator incompatible protocol Brain metastases require therapy Absolute neutrophil count le 1500/mm3 Platelet count less 100 000/mm3 Bilirubin great 1.5 mg/dl ( &gt; 26 μmol/L , System International ( SI ) unit equivalent ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg/dl ( &gt; 132μmol/L , SI unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Treatment investigational drug ; chemotherapy hormone therapy ( exclude Lutenizing Hormone Releasing Hormone ( LHRH ) agonists bisphosphonates provide lesion MR ( magnetic resonance ) image arise bone ) participation another clinical study within past four week start therapy concomitantly study Patients unable comply protocol Active alcohol drug abuse History autoimmune disease History allergy gadolinium intravenous ( IV ) contrast agent , indwell medical device condition would preclude MR scan Patients require ongoing use dexamethasone , antihistamine , antihypertensive medication control cardiac failure diuretic , likely need alteration dose study period . Dose adjustment medication may independently alter vascular permeability blood flow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>